The acquisition of Proteintech Genomics signals a strategic pivot toward combining transcriptomic data with protein analysis at both single-cell and spatial resolutions. Michael Schnall-Levin, chief technology officer at 10x Genomics, noted that the company views this integration as the next frontier for biological research. By folding these new capabilities into its infrastructure, the firm aims to provide more comprehensive datasets for scientific discovery. Despite the acquisition, 10x Genomics stated that the move is unlikely to cause any significant shifts in its financial outlook for the coming months.